Adoptive therapy for EBV-induced cancers: driving success with post-transplant lymphoproliferative disorder to other EBV-derived tumors. (May 2015)

• Record Type: Journal Article
• Authors: Smith, Corey; Khanna, Rajiv
• Is Part Of: Immunotherapy. Volume 7:Number 5(2015:May)
• Page Start: 563
• Page End: 572
• Publication Date: 2015-05
• Subjects: adoptive immunotherapy -- EBV -- NPC -- PTLD -- T cells; Immunotherapy -- Periodicals; 615.37
• DOI: 10.2217/imt.15.7
• Languages: English
• ISSNs: 1750-743X

Abstract

Epstein–Barr virus (EBV) infection is associated with a range of human malignancies of lymphocytic and epithelial cell origin. In addition to viral-mediated and genetic oncogenic events that lead to the establishment of EBV-associated malignancies, defects in the immune control of EBV likely play a significant role in promoting the survival of malignant cells. This breakdown in immune surveillance is most evident in immunocompromised transplant patients who are susceptible to the development of post-transplant lymphoproliferative disorders. Observations over the last two decades have shown that reconstitution of EBV-specific cellular immunity via adoptive cell therapy can have a dramatic effect on both preventing and treating post-transplant lymphoproliferative disorders, leading to hope that similar strategies could be effective in preventing more prevalent EBV-associated malignancies.